facebook button TROPION-Lung05: DS-1062a in NSCLC with actionable genetic mutations
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

TROPION-Lung05: DS-1062a in NSCLC with actionable genetic mutations

Sponsor: Daiichi Sankyo, Inc.

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Kinase Inhibitor Therapy and Platinum-based Chemotherapy (TROPION-Lung05).

For more information please contact the clinical research department: 631-675-5075